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Introduction: Incidence of use for various renal replacement therapies is well known, but no
data are available on the use of conservative treatment.
Objective: To assess the proportion of patients with chronic kidney failure receiving conser-
vative treatment.
Results: From July 1, 2013 to June 30, 2014, 232 patients with stage 5 CKD were seen in
the Nephrology Department. After having received information on the existing therapeu-
tic options and having known the opinion of their physicians, 81 patients (35%) selected
haemodialysis, 56 (24%) preferred peritoneal dialysis, 5 (2%) selected a preemptive trans-
plant from a living donor, and in 90 (39%) a conservative treatment option was selected.
In a univariate analysis using logistic regression, variables associated to a preference for
conservative treatment were age, Charlson index excluding age, walking difﬁculties, and
the level of functional dependendce, with the ﬁrst three factors achieving statistical signif-
icance in a multivariate analysis. Presence of a severe disease with a poor prognosis was
the main reason for selecting a conservative treatment (49%), with the second one being
symple, patients refusal to receive a renal replacement therapy (26%).
Mortality rate was 8.2/100 patient-months in conservative therapy group versus 0.6/100
patient-months in patients receiving renal replacement therapy (p<0.001). In patients
receiving conservative therapy, baseline glomerular ﬁltration rate at the time of study enroll-
ment was the only variable showing a signiﬁcant impact on survival.
Conclusions: About 39%of patientswith stage 5 CKD seen over a 1-year period in theNephrol-
ogy Department received conservative therapy. Age, co-morbidity, and functional disability
were the factors associated to selecting a conservative therapy option.© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española
frología. This is an open access article under the CC BY-NC-ND licensede Ne(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Elección de tratamiento conservador en la enfermedad renal crónica
Palabras clave:
Enfermedad renal crónica
en estadio 5
Tratamiento conservador
r e s u m e n
Introducción: La incidencia de las diversas modalidades de tratamiento sustitutivo renal es
conocida, pero no sucede así con la opción de tratamiento conservador.
Objetivo: Conocer la proporción de pacientes con insuﬁciencia renal crónica sometidos a
tratamiento conservador.
Resultados: Entre el 1 de julio de 2013 y el 30 de junio de 2014 fueron atendidos en el Ser-
vicio de Nefrología 232 casos con ERC en estadio 5. Tras recibir una información sobre las
diversas alternativas terapéuticas y con la opinión del médico responsable, 81 enfermos
(35%) optaron por el tratamiento con hemodiálisis, 56 (24%) mostraron preferencia por la
diálisis peritoneal, 5 (2%) por el trasplante de vivo prediálisis, y en 90 enfermos (39%) se
decidió realizar tratamiento conservador. En el análisis univariante de regresión logística
las variables asociadas a la elección de tratamiento conservador fueron la edad, el índice de
Charlson sin contar la edad, el grado de diﬁcultad para la marcha y el grado de dependen-
cia funcional, quedando los 3 primeros con signiﬁcación signiﬁcativa en el análisis multiva-
riante. La existencia de una enfermedad grave con mal pronóstico a corto plazo fue la princi-
pal causa por la que se indicó el tratamiento conservador (49%), y la segunda fue la negativa
del enfermo a recibir tratamiento sustitutivo renal (26%).
La tasa de mortalidad fue de 8,2/100 enfermos-mes en el grupo de tratamiento conser-
vador y de 0,6/100 enfermos-mes en el grupo que decidió optar al tratamiento sustitutivo
renal (p < 0,001). En el grupo tratado de forma conservadora, el ﬁltrado glomerular en el
momento de inclusión en el estudio fue la única variable que inﬂuyó de forma estadística-
mente signiﬁcativa sobre la supervivencia.
Conclusiones: El 39% de los pacientes con ERC en estadio 5 atendidos durante un an˜o en el
Servicio de Nefrología fueron tratados de forma conservadora. Edad, comorbilidad y dis-
capacidad funcional fueron las variables que se relacionaron con la elección de tratamiento
conservador.
© 2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española
de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-NDIntroduction
The distribution of patients into the different modalities of
renal replacement therapy is known, however it is not clear
the percent of patients that end up undergoing conservative
treatment. The study “Epidemiology of Chronic Renal Disease
in Spain” (Epidemiología de la Insuﬁciencia Renal Crónica en
Espan˜a, EPIRCE) showed that the prevalence of CKD-5 is in
Spain is 0.03%, which is 300 patients per million inhabitants.1
According to the data from the Dialysis and Transplant Reg-
istry of the Spanish Society of Nephrology, 120 patients per
million inhabitants started dialysis treatment or had an antic-
ipated renal transplantation in the year 2012.2 Based on these
data, it could be inferred that around 60% of the patients with
CKD-5 do not receive renal replacement therapy due to one
of the following reasons: they were poor candidates for such
a therapy, they die for unknown reasons or it is also possible
that they were not aware that the suffered from renal disease.
There is little information available on the percentage of
patients with CKD on conservative therapy and the available
data is very variable due to the great disparity of the popula-
tion under analysis.3 Table 1 shows a summary of the main
studies that have been published. The numbers concerning
Spain4,6,14 are very far from what we would have expected to
obtain when the data from the EPIRCE study and the incidence(http://creativecommons.org/licenses/by-nc-nd/4.0/).
of renal replacement therapy were compared. The data from
hospitals in other countries also vary signiﬁcantly according
to the critera of selection.5,7–13
The Ramon y Cajal hospital in Madrid provides healthcare
assistance to a population of 550,000 inhabitants. Any patient
who needs renal replacement therapy is attended in the Hos-
pital Nephrology Service, and the incidence and prevalence of
the various options of treatment are known. To determine the
percentage of patients who are being treated conservatively,
we have initiated a registry including all patients suffering
from CKD-5 who were attended in the Nephrology Service.
Below, we show our experience during the ﬁrst 12 month
period of our registry.
Materials and method
Since 1/7/2013, all the patients with stage-5 CRD who were
attended in the different areas of the Nephrology Service
of the Ramon y Cajal hospital (inpatient consultation, out-
patient consultation, hospitalisation and interconsultations
from other services) were incorporated into a registry in which
basic clinical and analytical data were gathered. Patients who
had renal transplantswere excluded. The glomerular ﬁltration
rate was estimated by the MDRD4-IDMS formula.
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Table 1 – Percentage of patients undergoing conservative treatment for CRD in different published series.
Renal function Other inclusion criteria With conservative
treatment
Garcia et al., 19974 Creatinine clearance <10ml/min/1.73m2 39/155 (25.2%)
Joly et al., 20035 Creatinine clearance <10ml/min/1.73m2 Age ≥80years 37/144 (25.7%)
Garcia et al., 20076 Stage-5 CRD 37/266 (13.9%)
Murtagh et al., 20077 Stage-5 CRD Age >75years 77/129 (59.7%)
Carson et al., 20098 Stage-4 and stage-5 CRD Age >70years 29/202 (14.3%)
Chandna et al., 20119 Stage-5 CRD 155/844 (18.4%)
Da Silva et al., 201210 Stage-4 and stage-5 CRD 30/170 (17.6%)
Morton et al., 201211 Stage-5 CRD 102/721 (14.1%)
Seow et al., 201312 Glomerular ﬁltration 8–12ml/min/1.73m2 Age ≥75 years or Charlson index ≥8 63/101 (62.4%)
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sHussain et al., 201313 Glomerular ﬁltration <20ml/min
Quirós et al., 201414 Stage-4 and stage-5 CRD
An essential section of the registry refers to the thera-
eutic option chosen after the patient and his/her family
ad received detailed information regarding all the existing
ethods (haemodialysis, peritoneal dialysis, renal transplant
nd conservative treatment). The indication for conserva-
ive treatment was always agreed upon with the patient and
is/her family, and this decision was registered in his/her
edical record and in the issued clinical report. In these
ases, the main reason for which a patient was not consid-
red to be a candidate for renal replacement therapy was also
equested,with oneof the followingﬁvepossibilities to be cho-
en: acute disease not curable by dialysis or renal transplant
nﬂuencing short-term survival, functional deterioration, gait
ifﬁculties, cognitive deﬁcit-signiﬁcant psychiatric disorder,
r the patient’s decision.
The date of inclusion in the registry is the date of the ﬁrst
isit the patient made to the Nephrology Service in the period
f time under analysis, and the clinical and analytical data
orrespond to that moment. The follow-up period for each
atient begins on the date of inclusion and ends on the date
he patient passed away or on the day the study ﬁnalised
30/6/2014). Patients who started renal replacement therapy
ere not ruled out at the beginning of it.
To ensure that the population sample was complete, we
sked the Biochemistry Department for a correspondence of
ll the analysis requests submitted by the Nephrology Ser-
ice between 1/7/2013 and 30/6/2014, in which the glomerular
ltration rate was under 15ml/min/1.73m2. After ruling out
ransplant patients and cases of acute renal failure or of
eversible deterioration in renal function in patients with CRD,
ll stage-5 CRD cases were identiﬁed and this population was
ompared to the one from the existing registry. Cases not
ncluded previously were incorporated into the registry, tak-
ng into account the date of inclusion of the ﬁrst blood test
ith glomerular ﬁltration rate <15ml/min/1.73m2, and clini-
al data were recovered retrospectively.
As a comorbidity indexweused theCharlson indexwithout
aking into account the age component. Functional dete-
ioration was assessed using the Barthel index15 and gait
bnormalities using the FAC scale.16 If the score in the Barthel
ndex is below 60, the patient is considered to be dependent
n order to carry out basic daily life activities (from 40 to 55,
he dependency degree is considered moderate, from 20 to
5 the dependency is severe and below 20, the patient is con-
idered fully dependent). The gait FAC scale has six categoriesAge >70years 172/441 (39%)
Patients referred to a decision aid programme 48/569 (8.4%)
(0: patient cannot walk; 1: patient walks with difﬁculty held
by another person; 2: patient needs support from another
person to walk; 3: patient can walk only under supervision;
4: patient can walk independently on level ground, but
requires help on stairs; 5: patient can walk independently any-
where). If the score on the FAC scale is between 0 and 1, it is
considered that the patient has acute gait abnormalities, if the
score is between 2 and 3, the disorder is considered moderate,
and if the score is between 4 and 5, it is considered that there
are no gait abnormalities or that they are mild.
The patients who were assigned conservative treatment
were given the option to continue the follow-up at the chronic
renal disease division of the Nephrology Service or at the Pal-
liative Care Unit. All the patients who were given care in the
chronic renal disease division followed the same care protocol
that was applied to the patients who chose the renal replace-
ment therapy alternative. The patients who were attended at
the Palliative Care Unit followed the speciﬁc protocol that was
previously described for these cases.17
Statistical analysis
The glomerular ﬁltration rate, the Charlson index and
the follow-up time have normal distributions (Kolmogorov–
Smirnov test), and the results are expressed as mean±SD.
Age does not follow a normal distribution and is expressed
as median and interquartile range. The comparison of the
numeric variables with normal distribution was performed
using the analysis of variance (ANOVA) or the Student’s t-test,
and for age we used the Mann–Whitney test. The qualita-
tive variables are expressed as percentages of the population
under study and they were compared using Fisher’s tests
and the Chi-square test; to evaluate the degree of associ-
ation between qualitative variables we used the Cramer’s
V coefﬁcient that ranges between 0 (no association) and 1
(perfect association). To evaluate the dependence between
the option for conservative treatment and certain variables,
we carried out a logistic regression analysis, submitting the
adjusted odds ratio (OR) and the conﬁdence interval (CI) of
95%. To analyse the predictor variables for mortality within
the group treated conservatively, we used the Cox propor-
tional hazards model. A p<0.05 was considered statistically
signiﬁcant.
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Table 2 – Clinical and analytical data according to the therapeutic option chosen.
Renal replacement therapy (n=142) Conservative treatment (n=90)
Age (interquartile range) 68 (54, 76) 83 (78, 86) p<0.001
Male patients 89 (63%) 52 (58%) p=0.544
Glomerular ﬁltration 11.5±2.8 11.4±2.8 p=0.910
Vascular nephropathy 36 (25%) 21 (23%) p=0.848
Diabetic nephropathy 31 (22%)
Charlson index (no age) 4.7±2.1
Results
Between1/7/2013 and30/6/2014, 232patientswith stage-5CRD
were attended at the Nephrology Service. These patients were
not given dialysis nor were they transplanted. 206 patients
were prospectively included in the CRD registry; the other
26 were retrospectively incorporated after being identiﬁed in
the patients’ correspondence provided by the Biochemistry
Service. There are 141 males (61%) and 91 females (39%),
their age ranging between 15 and 93 (median age is 75,
interquartile range 66, 82). The aetiologies of renal disease
were: vascularnephropathy (25%), diabeticnephropathy (24%),
glomerulonephritis (12%), interstitial nephritis (8%), polycystic
kidney disease (6%), other nephropathies (11%) and unknown
origin (14%). Glomerular ﬁltration rate at the moment of incor-
poration in the registry was 11.5±2.8ml/min/1.73m2 (range
3.2–14.9ml/min/1.73m2).
After receiving information regarding the different ther-
apeutic alternatives and with the advice of the physician in
charge, 81 patients (35%) opted for haemodialysis treatment,
56 (24%) preferred peritoneal dialysis, 5 (2%) preferred predial-
ysis living donor renal transplantation, and 90 patients (39%)
decided to undergo conservative treatment. Table 2 shows the
most relevant clinical data at themoment of inclusion in treat-
ment according to the chosen therapeutic option.
The 142 patients who opted for renal replacement therapy
were younger (median age was 68, interquartile range 54,
76) (p<0.001), and their Charlson index was lower (4.7±2.1)
(p<0.001) than the 90 patients from the conservative treat-
ment group. The degree of functional deterioration and gait
abnormalities were very selective variables between both
groups of patients (Table 3). The level of association between
these variables and the decision to undergo conservative
treatment was slightly higher for the degree of gait abnor-
mality (V=0.50) than for the degree of dependence (V=0.45).
Table 3 – Degree of functional deterioration (Barthel index) and
therapeutic option chosen.
Renal replacement th
Degree of functional deterioration
Fully dependent (Barthel 0–15) 0
Severely dependent (Barthel 20–35) 1(1%
Moderately dependent (Barthel 40–55) 5 (3%
Non-relevant dependency (Barthel 60–100) 136 (96
Degree of gait abnormality
Acute disorder (FAC 0 or 1) 0
Moderate disorder (FAC 2 or 3) 13 (9%
Non-relevant disorder (FAC 4 or 5) 129 (9124 (27%) p=0.493
5.8±1.9 p<0.001
Functional deterioration and gait abnormalities are closely
related variables (p<0.001, Cramer’s V coefﬁcient = 0.60).
In the univariate analysis of the logistic regression (in
which we used as dichotomous dependent variable the deci-
sion to undergo conservative treatment or renal replacement
therapy), age, the Charlson index, degree of dependence and
degree of gait abnormalities were associated with the choice
of conservative treatment. In the multivariate analysis, age,
degree of gait abnormalities and the Charlson index reached
statistical signiﬁcance (the latter being on the edge of statisti-
cal signiﬁcance) (Table 4).
Table 5 shows the value of the Charlson index and the
percentages of dependent patients, patients with gait abnor-
malities, and patients with conservative treatment by age
group. The Charlson index shows a lower value, with statisti-
cal signiﬁcance, in the age group of patients below the age of
65, compared to the other two groups. There is no statistically
signiﬁcant difference between the two groups above that age.
The main reason for which a patient was not consid-
ered as a candidate for renal replacement therapy, of which
there were 44 patients (49%), was due to the existence of
an acute concomitant disease, which was not expected to
improve with dialysis or transplantation and which inﬂu-
enced short-term prognosis, 13 cases (14%) were due to
the degree of functional dependence and gait abnormalities,
and 10 patients (11%) due to dementia or acute psychi-
atric disorder. The other 23 patients (26%) turned down the
option to undergo renal replacement therapy even though
there was no absolute contraindication against it. Compared
to the 67 patients who had contraindications for dialysis,
the 23 patients voluntarily included in the conservative ther-
apy were older (median age was 86 vs 82, p=0.010) and
had a lower Charlson index (4.1±1.2 vs 6.4±1.7, p<0.001).
The patients’ decision to undergo conservative treatment
increased with age: 1 patient out of the 13 conservatively
treated was below the age of 75 (8%), six patients out of 39
of gait abnormalities (FAC scale) according to the
erapy (n=142) Conservative treatment (n=90)
8 (9%)
p<0.001
V=0.45
) 11(12%)
) 16 (18%)
%) 55 (61%)
16 (18%)
p<0.001
V=0.50
) 31 (34%)
%) 43 (48%)
nefrolog ia. 2015;35(3):273–279 277
Table 4 – Variables associated with the decision to undergo conservative treatment.
Univariate analysis Multivariate analysis Final model
OR (95% CI) OR (95% CI) OR (95% CI)
Age (years) 1.21 (1.15–1.28) p<0.001 1.21 (1.14–1.29) p<0.001 1.21 (1.14–1.29) p<0.001
Female gender 1.23 (0.72–2.10) p=0.457
Diabetic nephropathy 1.30 (0.70–2.41) p=0.400
Vascular nephropathy 0.90 (0.48–1.66) p=0.727
Charlson index excluding age 1.31 (1.14–1.51) p<0.001 1.23 (1–1.5) p=0.047 1.23 (1–1.5) p=0.045
Degree of dependence 6.76 (3.10–14.77) p<0.001 1.85 (0.6–5.74) p=0.287
Degree of gait abnormality 8.46 (4.36–16.42) p<0.001 3.99 (1.4–11.39) p=0.009 5.86 (2.55–13.48) p<0.001
Table 5 – Charlson index (no age) and percentages of patients with dependence, gait abnormalities and election
of conservative treatment, according to age group.
Years <65 65–79 ≥80
No. 57 93 82
Charlson index 4.4±2.2a,b 5.3±2a,c 5.5±1.9b,c p=0.005
Dependents (Barthel < 60) 3 (5%) 12 (13%) 26 (32%) p<0.001
With gait abnormalities (FAC 0–3) 5 (9%) 19 (20%) 36 (44%) p<0.001
Conservative treatment 3 (5%) 22 (24%) 65 (79%) p<0.001
a p=0.008.
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Initial decision
Haemodialysis
n=81
HD initiation
n=29
Initial decision
peritoneal dialysis
n=56
Initial decision
conservative treatment
n=90
Initial decision
living donation
n=5
n=4
Deceased
n=3
Ongoing
n=45
HD initiation
n=2
PD initiation
n=13
Ongoing
n=31
HD initiation
n=1
Living donation
n=4
HD initiation
n=1
Deceased
n=36
Ongoing
n=53
Cadaveric transplant
n=10
Deceased 3
Cadaveric transplant
Fig. 1 – Patient evolution according to therapeutic optionb p=0.002.
c p=0.585.
etween the age of 75–84 (15%) and 16 patients out of 38 were
5 or older (42%) (p=0.007).
Fig. 1 shows the evolution of the patients according to
he therapeutic option chosen at the beginning. During the
2 months of the study, 64 patients started renal replace-
ent therapy: 33 (52%) were treated with haemodialysis,
3 (20%) with peritoneal dialysis, and 18 (28%) received
nticipated renal transplants (four from living donors and
4 from cadaver grafts). The glomerular ﬁltration at the
tart of renal replacement therapy was the following:
aemodialysis 5.5±2.6ml/min/1.73m2; peritoneal dialysis
.4±3.5ml/min/1.73m2 and anticipated renal transplant 8.4±
.8ml/min/1.73m2 (p=0.003 between haemodialysis and peri-
oneal dialysis, p<0.001 between haemodialysis and anti-
ipated renal transplant).
40% of the patients assigned to the conservative treat-
ent group (36 cases) and 4% of the patients who had chosen
enal replacement therapy (six cases, all from the subgroup
hat had chosen treatment with haemodialysis; three passed
way before initiating said treatment) passed away. Due to
he higher mortality rate, the follow-up period was shorter for
he conservative treatment group (4.9±3.2 vs 7.2±3.7 months
p<0.001)). The mortality rate was 8.2/100 patients-month
n the conservative treatment group and 0.6/100 patients-
onth in the group that opted for renal replacement therapy
p<0.001).
In the group of patients treated conservatively,we analysed
he inﬂuence of the different variables related to mortality
sing the Cox proportional hazards model. Evaluated individ-
ally, age, gender and primary renal disease variables were
ot associated with mortality, but the Charlson index was,
egardless of age (regression coefﬁcient: 0.185, p=0.029), the
lomerular ﬁltration at the moment of inclusion in the study
regression coefﬁcient: −0.238, p<0.001), the assignation to
onservative treatment due to medical contraindication and
chosen at the start.
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not voluntarily (regression coefﬁcient: 0.309, p=0.041), the
degree of dependence (regression coefﬁcient: 0.391, p=0.006),
and the degree of gait abnormality (regression coefﬁcient:
0.567, p=0.010). When we built a Cox model with these ﬁve
variables, only the glomerular ﬁltration continued inﬂuencing
mortality with statistical signiﬁcance and of protective type
(regression coefﬁcient:−0.256;OR: 0.77, CI: 0.67–0.88, p<0.001).
Out of the 90 patients assigned to conservative treatment,
41 (46%) were voluntarily given care in the Palliative Care Unit
(sixwere transferred to a half-stay hospice and 35were treated
within the Home Care Program).
By 30/6/2014, 129 patients with stage-5 CRD were receiv-
ing care at the Nephrology Service. These patients were
not given dialysis nor were they transplanted. Out of those
patients, 76 (59%) chose to receive renal replacement ther-
apy (45 chose haemodialysis and 31 peritoneal dialysis) and
53 (41%) remained with the conservative treatment option.
Discussion
During the 12 months of the study, 64 patients from the con-
trol population of the Ramon y Cajal Hospital began renal
replacement therapy for the ﬁrst time. The annual incidence
of new patients (116.4patients/million inhabitants) is similar
to that of the national registry and slightly higher than that
of the autonomous registry of Madrid (104.6patients/million
inhabitants in 2012).18
If the data from the EPIRCE study are comparable to our
region, for the population given care at the Ramon y Cajal Hos-
pital, there must be around 165 patients with stage-5 CRD. If
we assume that this population remains stable over time due
to the natural ﬂow of incoming and outgoing patients, accord-
ing to our incidence of patients who begin renal replacement
therapy, we must consider that about 101 patients (61% of
the patients with stage-5 CRD) do not come to undergo dial-
ysis or renal transplants due to various reasons (decision to
undergo conservative treatment, death, hidden disease). The
rate of conservative treatment in patients with stage-5 CRD
monitored at the Nephrology Service is 39% if we calculate it
from a total of 232 patients given care at the Nephrology Ser-
vice during one year, and 41% in 129 patients monitored the
day the study was ﬁnalised. To these percentages we should
add 1% corresponding to the three patients who chose renal
replacement therapy and died before starting treatment, but
we are still far from the theoretical percentage comprising 61%
of patients with stage-5 CRD who ultimately would not receive
renal replacement therapy.
By 30/6/2014, the Nephrology Service was monitoring
129 patientswith stage-5 CRD. To achieve the number in accor-
dance with the EPIRCE study (165 cases), we lack 36 more
patients. It is possible that their renal disease was not yet
diagnosed or that they were being assisted at other services or
healthcare institutions. It is possible that the majority of these
last cases were not referred to the Nephrology Service because
their doctors did not consider them to be candidates for renal
replacement therapy, and if they had been taken into account
they would have increased the rate of patients treated con-
servatively and we would have come closer to the theoretical
number.;35(3):273–279
In our series, as well as in the rest of the series
published,4,9,10,13,19 and as expected, patients treated con-
servatively are characterised as being elderly patients with
comorbility as compared to thepatientswho chose the various
options for renal replacement therapy. Functional capacity, as
measured by degree of dependence and gait abnormalities,
has been a clearly differentiating factor between both groups
of patients. It is possible that in the decision to indicate renal
replacement therapy, the impact on functional capacitywill be
more important than age and comorbility.10 Functional deteri-
oration was the main cause to not include patients for dialysis
in the Garcia et al. series of 1997.4 However, in our series, when
asked what was the main reason for choosing conservative
treatment, the most common cause was the existence of an
acute disease inﬂuencing short-term survival (49% of the total
of the cases). Functional deﬁciency was only claimed as the
main reason in 14% of the cases, which indicates that the
prognosis of the clinical condition had more inﬂuence than
the functional impact.
The patient’s refusal to undergo dialysis treatment is
especially relevant, and in 26% of our cases it was the reason
for including them in the conservative treatment group. In
the series of the Gregorio Maran˜ón Hospital from Madrid, the
patient’s decision was the reason for exclusion from dialysis
treatment in 14.6% of the patients given care within the home
care program.19 In the ﬁrst study conducted at the Nephrology
Service at the Parc Taulí Healthcare Corporation in Sabadell,
the patient’s decision was the reason for conservative treat-
ment in 25.6% of the cases, the same percentage as ours.4 In
the following review, this percentage increased to 35.1% and
was the ﬁrst reason to not assign patients to dialysis
treatment.6 In our series, the patients who refused
dialysis treatment had a lower comorbility rate than the
rest of the patients in conservative treatment, data that are in
line with the absence of medical contraindications to undergo
dialysis treatment in these patients. Old age was the main
variable associated with this decision.
As a consequence of population ageing, the incidence and
predominance of elderly patients who reach stage-5 CRD
increase exponentially. There are publications that show pos-
itive results regarding dialysis treatment in the elderly.20,21 As
an isolated variable, age should not be a factor in determining
indication for renal replacement therapy, and this choice was
taken into account for all patients in our series, regardless of
age. Nevertheless, it is clear that age is associated with the
election of conservative treatment.19 In our series, this asso-
ciation was considered of statistical signiﬁcance both in the
univariate and multivariate logistic regression analysis. In
the analysis by age groups, the percentage of patients with
conservative treatment clearly increases with age, just as the
degree of dependence and the degree of gait abnormalities
increase. This increase cannot be attributed to a higher comor-
bility (the Charlson index stabilised in patients age 65 and
older), but to a progression in the functional disability rate
that comes with age, and to the patient’s decision, which was
themain cause for not assigning patients to dialysis treatment
in the oldest age group.
During the 12 months under study, 64 patients started
renal replacement therapy (33 with haemodialysis, 13 with
peritoneal dialysis, and 18 with anticipated renal transplant).
15;35
E
c
t
p
o
r
p
r
h
t
w
v
a
a
P
a
i
i
t
p
b
c
o
C
T
r
1
1
1
1
1
1
1
1
1
1
2
on dialysis. Nephron Clin Pract. 2010;115:c28–34.nefrolog ia. 20
xcept for the anticipated renal transplant, there were few
hanges between the therapies chosen at the beginning and at
he end (two patients who had chosen peritoneal dialysis, one
atient who had a renal transplant from a living donor and
ne patient undergoing conservative treatment began renal
eplacement therapy with haemodialysis at the end).
The mortality rate was greatly higher in the group of
atients assigned to conservative treatment: the mortality
ate, expressed in 100 patients-month, was almost 14 times
igher than that of patients who opted for renal replacement
herapy. We must take into consideration that all the patients
ith stage-5 CRD who were assisted at the Nephrology Ser-
ice were included in the study, and many of them were at
n advanced stage of the disease. In fact, 46% of the patients
ssigned to conservative treatment were transferred to the
alliative CareUnit;most of themwere receivingHomeCare.17
It is clear that our data correspond to the patients attended
t the Nephrology Service and do not include the cases mon-
tored at other services or healthcare institutions nor do they
nclude the population with hidden disease in this situa-
ion. However, they provide information on the percentage of
atients undergoing conservative treatment. These data must
e taken into account and compared to the experience at other
entres in order to gain precise knowledge of the magnitude
f this problem.
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